FDA Approves Vemlidy® (tenofovir alafenamide) for Chronic Hepatitis B in Adults
November 21, 2016
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Summary:
On November 10, 2016, the U.S. Food and Drug Administration (FDA) approved Vemlidy® (tenofovir alafenamide), a once-daily oral treatment for chronic hepatitis B infection in adults.
The U.S. Food and Drug Administration (FDA) has approved Vemlidy® (tenofovir alafenamide) for the treatment of chronic hepatitis B infection in adults. Vemlidy® is administered as a 25-mg once-daily treatment. The active ingredient in Vemlidy® is a targeted prodrug of tenofovir that allows for lower dosing and more efficient liver targeting than Viread® (tenofovir disoproxil), a previously approved drug used to treat hepatitis B and HIV.
Vemlidy® is manufactured and marketed by Gilead Sciences, Inc.
Now there are more options to treat #HepB in adults - FDA approves Vemlidy® (tenofovir alafenamide): http://bit.ly/2f7vPlT
Posted In:
Prevention and Wellness
Public Health and Safety
